Skip to content

Superficial and Deep Endometriosis: Role of Systemic Inflammation as a Marker of Clinical, Surgical, and Reproductive Outcomes

Superficial and Deep Endometriosis: Role of Systemic Inflammation as a Marker of Clinical, Surgical, and Reproductive Outcomes

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06470594
Acronym
ESPRIMO-CCR
Enrollment
138
Registered
2024-06-24
Start date
2024-05-29
Completion date
2026-06-30
Last updated
2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometriosis

Brief summary

Primary aim of this study is to evaluate the change in systemic inflammation parameters after surgery for superficial, ovarian or deep endometriosis. Secondary objectives focus on correlating these parameters to clinical outcomes, in patients with pelvic pain, and reproductive outcomes, in women desiring offspring. Participants already scheduled for surgery as part of their endometriosis care will be followed regarding the abovementioned outcomes after calculation of pre and postsurgical systemic inflammation markers (neutrophil to lymphocyte ratio; platelet to lymphocyte ratio and lymphocyte to monocyte ratio)

Interventions

None listed

Sponsors

University of Campania Luigi Vanvitelli
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 45 Years

Inclusion criteria

* Age between 18 and 45 years. * Postoperative follow-up of at least 12 months; * Signature of informed consent regarding laparoscopic surgical treatment. * Signature of informed consent to the processing of personal data duly documented by medical records.

Exclusion criteria

* Failure to sign informed consent for laparoscopic surgical treatment * Histologic diagnosis of borderline tumor and/or ovarian carcinoma and/or mucinous cystadenoma and/or germ cell tumor or other malignancy of the genital tract * postoperative follow-up of less than 12 months; * documented history of inflammatory, rheumatologic, or immunologic disease; and * failure to provide informed consent for personal data processing.

Design outcomes

Primary

MeasureTime frame
Neutrophil to lymphocyte ratioMeasured before and after (24 to 72 hours) surgery

Secondary

MeasureTime frame
Platelet to lymphocyte ratioMeasured before and after (24 to 72 hours) surgery
Lymphocyte to monocyte ratioMeasured before and after (24 to 72 hours) surgery

Countries

Italy

Contacts

Primary ContactGaetano Riemma, MD
gaetano.riemma@unicampania.it0038 0815665599

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026